SS31 Peptide GuideElamipretide (Forzinity) for Mitochondrial Repair
SS-31 (also written SS31, and known by its pharmaceutical name elamipretide) is a mitochondria-targeting peptide that repairs the physical structure energy production depends on. It binds to cardiolipin — the lipid holding the inner mitochondrial membrane together — and restores the tight organization that efficient electron flow requires. This is structural repair, not stimulation.
At a Glance
- Tetrapeptide that targets and stabilizes the inner mitochondrial membrane
- Binds cardiolipin — the structural lipid anchoring the electron transport chain
- FDA-approved in 2025 as Forzinity for Barth syndrome (first mitochondria-targeted drug approved in the US)
- Improves ATP production in aging muscle within a single dose
- Typical protocol: 5–10 mg daily loading, then 2–3× per week maintenance
- Works by structural repair, not metabolic stimulation
- Dosing: Use our peptide calculator to calculate your injection volume
For mitochondrial context, see our MOTS-c Guide, NAD+ Guide, and Mitochondrial Stack.
What Is SS31 (Elamipretide)?
SS31 — also written SS-31 and known pharmaceutically as elamipretide (trade name Forzinity) — is a short peptide that concentrates inside mitochondria at levels roughly 5,000 times higher than surrounding tissue. This selective accumulation is what makes it effective: it reaches the inner membrane where energy production happens, not just the cell in general.
Its target is cardiolipin, a lipid unique to the inner mitochondrial membrane. Cardiolipin holds the respiratory chain complexes in position and maintains the tight membrane curvature needed for efficient electron transport. When cardiolipin is damaged or loses binding integrity, electron flow becomes turbulent, byproducts accumulate, and energy output drops — long before the mitochondria themselves fail.
SS-31 restores cardiolipin structure without altering upstream signaling. The result is cleaner electron flow, better membrane charge retention, and more ATP from the same signals.
How Mitochondria Break Down
The inner mitochondrial membrane loosens over time under normal life pressures. Each force is small, but together they erode the structure energy production depends on:
| Stressor | Mechanism |
|---|---|
| Chronic inflammation | Daily immune activity strains membrane lipid anchors |
| Illness/infection | Fever and immune response push mitochondria to maximum output |
| Poor metabolic health | Glucose swings and insulin resistance force harder work on weakened scaffold |
| Alcohol | Even moderate intake generates byproducts challenging membrane stability |
| Sleep disruption | Deep sleep is when membrane repair runs; fragmented sleep leaves restoration incomplete |
| Psychological stress | Stress hormones increase demand while suppressing repair windows |
| Age | Cumulative exposure to all of the above |
The result is familiar: effort feels costlier, recovery takes longer, and energy becomes easier to disrupt — not because fuel is lacking, but because the membrane scaffolding has weakened.
How SS-31 Works
SS-31 binds to cardiolipin on the inner mitochondrial membrane and restores the structural tension that keeps respiratory machinery aligned. Once structure is recovered:
Electron flow becomes cleaner: Respiratory complexes remain in position, reducing turbulence in the chain and minimizing electron leak.
The membrane holds its charge more reliably: A tighter membrane sustains the electrochemical gradient required for continuous ATP production.
Mitochondria experience less internal strain: Cleaner flow produces fewer reactive oxygen species, allowing each mitochondrion to function longer before requiring replacement.
Tissues meet demand with less effort: When machinery moves electrons efficiently, work produces proportionate fatigue rather than exaggerated strain.
These are structural corrections, not forced output. SS-31 does not stimulate the system — it restores the architecture that makes clean energy possible.
SS-31 Benefits
Energy stability
When the membrane is restored, energy becomes more predictable under load. Physical effort produces proportional fatigue instead of delayed crashes. Recovery windows shorten because tissues can power repair programs cleanly rather than working against internal inefficiency.
Daily variability narrows. A poor night's sleep, a missed meal, or a mild illness still registers, but the impact is smaller because the underlying machinery remains stable.
ATP production in aging
Human studies confirm SS-31 reaches its target and improves function in aging tissue. A single IV dose increased skeletal-muscle ATP production in older adults — demonstrating target engagement in the population most affected by mitochondrial decline.
Cardiac function
In failing human heart tissue, SS-31 exposure improved mitochondrial respiration. Clinical trials in Barth syndrome (a genetic disorder of cardiolipin remodeling) showed improvements in cardiac biomarkers and functional capacity over years of treatment — the basis for FDA approval.
NAD+ conservation
SS-31 reduces the cellular "NAD+ burn rate" by fixing structural problems that waste it. When the membrane is stable:
- Electron flow stops leaking, reducing oxidative byproducts
- PARP-driven DNA-repair penalty shrinks (PARP consumes NAD+ when fixing oxidative damage)
- Inflammatory signals that drive CD38 expression quiet down (CD38 degrades NAD+)
Net effect: cells don't just make energy more efficiently — they spend far less NAD+ doing it.
Who SS-31 Benefits
SS-31 is used when life loads the mitochondrial membrane beyond its ability to maintain structure. Across these contexts, the principle is the same:
| Profile | Why SS-31 Helps |
|---|---|
| Aging adults | Restores membrane tension that declines with age; stabilizes daily energy |
| GLP-1/retatrutide users | Supports mitochondrial hardware during high oxidative flux from rapid fat loss |
| Low-energy phenotypes | Addresses structural instability underlying chronic fatigue and post-exertional malaise |
| Post-viral recovery | Re-establishes clean energy production after immune activation stresses membranes |
| High physical demand | Athletes, shift workers, sustained cognitive load — reduces mitochondrial strain accumulation |
| Hormonal transition | Peri-menopause, andropause — stabilizes energy under increased inflammatory and sleep disruption |
Dosing
SS-31 behaves as a structural repair signal rather than continuous therapy. Once membrane sites are saturated, adding more SS-31 doesn't increase the effect.
Reconstitution note: Use bacteriostatic water with sodium chloride (isotonic) to reduce injection site sting and prevent welts. Use the reconstitution calculator to determine exact volumes.
Standard protocol
| Phase | Dose | Duration | Purpose |
|---|---|---|---|
| Loading | 5–10 mg daily | 5–10 days | Saturate membrane binding sites |
| Maintenance | 5–10 mg | 2–3× per week | Sustain structural integrity |
Timing
Morning or 60–90 minutes before training. The peptide is used intermittently — aligned with stressors rather than fixed schedules.
Administration
Subcutaneous injection. The peptide is well tolerated; transient warmth or brief nausea may occur early and typically resolve quickly. Mild fatigue is expected during loading if baseline mitochondrial damage is significant — this reflects the repair process.
Clinical Research and FDA Approval
Barth syndrome (FDA approved)
SS-31 (as elamipretide/Forzinity) received FDA accelerated approval in September 2025 for Barth syndrome — a genetic disorder defined by defective cardiolipin remodeling. This makes it the first mitochondria-targeted therapeutic approved in the United States.
The TAZPOWER trial showed multi-year improvements in 6-minute walk distance and cardiac biomarkers. A confirmatory post-marketing study is ongoing.
Other conditions (investigational)
| Indication | Trial | Result |
|---|---|---|
| Primary mitochondrial myopathy | MMPOWER-3 | Primary endpoint not met; secondary outcomes showed directional benefit |
| Older adults | ATPmax study | Single IV dose increased skeletal-muscle ATP production |
| Dry AMD | ReCLAIM-2 | Mixed results overall; functional signal in predefined subgroups |
| Failing human heart | Ex vivo study | Improved mitochondrial respiration in human myocardium |
Across studies, the mechanistic signal is consistent: SS-31 reaches its target, stabilizes the membrane, reduces byproduct formation, and improves efficiency. Functional outcomes vary by indication, but structural effects are reproducibly observed.
SS-31 + MOTS-c + NAD+ Stack
Mitochondrial performance depends on three things: structure, signaling, and cofactor availability.
| Component | Role |
|---|---|
| SS-31 | Repairs structure — electrons flow cleanly |
| MOTS-c | Activates adaptive signaling — more mitochondria, better fuel choice |
| NAD+ | Supplies cofactor — the redox currency mitochondria run on |
Together: better engines (SS-31) + more engines (MOTS-c) + fuel for both (NAD+). The result is a mitochondrial system that runs younger than its chronological age.
This combination is known as the Mitochondrial Integration & Transformation Triad (MITT). See: Mitochondrial Stack
Side Effects and Safety
Common:
- Transient warmth or flushing (early doses)
- Brief nausea (typically resolves quickly)
- Mild fatigue during loading phase (reflects repair process)
Rare:
- No serious adverse events dominant in published trials
The Barth syndrome trials — which included extended treatment over years — showed acceptable tolerability. The FDA approval reflects a positive benefit-risk assessment in a population with severe mitochondrial dysfunction.
Regulatory Status
FDA approved: Elamipretide (trade name Forzinity) received accelerated approval in 2025 for Barth syndrome. This is the first mitochondria-targeted drug approved in the US. A confirmatory post-marketing study is required under the accelerated-approval framework.
Other indications: For all non-Barth uses, elamipretide remains investigational. Access occurs through expanded-access programs and investigator-led protocols.
Why limited approvals: The constraint is economic — developing a specialized mitochondrial therapeutic across diverse chronic conditions is costly. The Barth syndrome approval reflects a focused strategy on a well-defined genetic population.
FAQ
What is SS31 peptide?
SS31 peptide (also written SS-31, and known pharmaceutically as elamipretide or Forzinity) is a tetrapeptide that targets the inner mitochondrial membrane. Unlike metabolic stimulants, SS31 works by repairing structure — specifically by binding and stabilizing cardiolipin, the lipid that holds the electron transport chain in position. The result is cleaner energy production with fewer byproducts. In September 2025, it became the first mitochondria-targeted drug approved by the FDA (for Barth syndrome).
What does SS-31 do?
SS-31 binds to cardiolipin on the inner mitochondrial membrane and restores structural integrity. This allows cleaner electron flow, more efficient ATP production, and reduced oxidative byproducts. It's structural repair, not stimulation.
How long does SS-31 take to work?
Effects begin rapidly — target engagement is measurable within hours. A loading phase of 5–10 days saturates membrane binding sites. Sustained benefits require intermittent maintenance dosing.
Is SS-31 FDA approved?
Yes, for Barth syndrome under the trade name Forzinity (September 2025). For all other uses, it remains investigational.
Can SS-31 help with aging?
Published data shows SS-31 improves ATP production in aging muscle and reduces markers of mitochondrial inefficiency. It's used intermittently — short repair phases spaced through the year — to restore alignment and maintain steadier daily output.
How is SS-31 different from MOTS-c?
SS-31 repairs mitochondrial structure (the hardware). MOTS-c activates adaptive signaling to build more mitochondria and improve fuel selection (the software). They're complementary — most effective when combined with NAD+ support.
What's the best dosing protocol for SS-31?
Start with a loading phase of 5–10mg daily for 5–10 days to saturate cardiolipin binding sites. Then maintain with 5–10mg 2–3 times per week. Morning dosing or 60–90 minutes before training works best. Unlike MOTS-c, SS-31 is structural repair—once binding sites are occupied, more doesn't help. Higher doses don't produce proportionally better effects.
How do I reconstitute and store SS-31?
Reconstitute with isotonic bacteriostatic water (containing 0.9% sodium chloride) to minimize injection site reactions. Plain BAC water works but may cause more sting. Store lyophilized powder refrigerated or frozen; once reconstituted, keep at 2–8°C and use within 4–6 weeks. Protect from light and temperature fluctuations.
Can I combine SS-31 with NAD+?
Yes, and they're synergistic. SS-31 repairs membrane structure so electrons flow cleanly, which reduces the NAD+ burn rate (less oxidative damage means less NAD+ spent on repair). Adding NAD+ support (IV or IM, not just oral) ensures the cofactor is available when the membrane can finally use it efficiently. This is the basis of the MOTS-c + SS-31 + NAD+ mitochondrial stack.
What side effects does SS-31 have?
Most people experience mild transient effects: brief warmth or flushing, occasional nausea that resolves quickly, and fatigue during the loading phase (especially if baseline mitochondrial function is poor). Serious adverse events are rare in published data. The long-term Barth syndrome trials showed acceptable tolerability over years of treatment.
How long should I run SS-31?
SS-31 works as a repair signal, not continuous therapy. Most practitioners recommend loading phases (5–10 days) followed by intermittent maintenance (2–3× weekly for 4–8 weeks), then breaks. Some use periodic "tune-up" cycles a few times per year rather than continuous dosing. The goal is restoring structure, not permanent saturation.
Where can I get SS-31?
For Barth syndrome, elamipretide (Forzinity) is now FDA-approved and available through specialty pharmacies. For other uses, it remains investigational and is available through research peptide suppliers, select compounding pharmacies, or expanded-access programs through clinicians. Quality varies significantly among research suppliers—look for third-party testing and certificates of analysis.
SS-31 for Mitochondrial Stability {#mitochondrial-stability}
This section covers SS-31 as an add-on module for advanced injury recovery—designed to layer on top of the 5-compound base protocol when relapse under load is the limiting factor.
The final bottleneck in injury recovery often isn't tissue structure—it's mitochondrial instability under stress. You progress for a few sessions, then flare. Fatigue becomes the limiter, not mechanics. The injury site feels biologically reactive, not simply weak.
SS-31 (Elamipretide) stabilizes mitochondrial output so repair can consolidate instead of repeatedly re-inflaming.
| Injury Recovery At a Glance | |
|---|---|
| Target | Cardiolipin on inner mitochondrial membrane |
| Goal | Reduce ROS spikes under stress; stabilize ATP production |
| When to use | Repair is structurally complete but relapses under load |
| Loading dose | 5–10 mg daily for 2–4 weeks |
| Maintenance dose | 5–10 mg 2–3× weekly |
| Cycle | 8–12 weeks |
Key principle: SS-31 is not a "healing peptide"—it's a stability layer that makes existing repair hold under stress.
Who This Is For
People who have:
- Completed foundational repair (BPC-157/TB-500)—blood flow restored, tissue warm and supple
- Established metabolic support (NAD+/GHK-Cu/KPV)—energy stable, collagen quality improving
- Optimized hormonal timing (Tesamorelin if needed)—sleep-timed repair functioning
- But still relapse under load—progress stalls when training intensity increases
Signs You Need This
- Progress for 2–3 sessions, then flare without obvious cause
- Post-session soreness/stiffness is disproportionate to load
- Recovery becomes unpredictable despite consistent programming
- Energy crashes specifically during periods of higher training stress
- The injury site feels "reactive" rather than just weak
- Fatigue becomes the limiter, not mechanics or pain
- You suspect metabolic stress is reactivating inflammation
Signs This Isn't the Right Next Step
- Tissue is still cold, stiff, or poorly perfused → More BPC-157/TB-500
- Energy crashes even at rest → More NAD+
- Sleep is still disrupted → Tesamorelin
- Neural symptoms persist (burning, tingling) → ARA-290
- The issue is clearly programming (too much volume/intensity) → Adjust training first
Do I Need the Base Protocol First?
Recommended but not required. SS-31 works best when layered on top of foundational repair:
| Scenario | Recommendation |
|---|---|
| Acute injury (<4 weeks) | Start with BPC-157 + TB-500 |
| Chronic injury with multiple bottlenecks | Start with 5-compound base protocol |
| Relapse under load is the clear limiter | SS-31 can be added to established protocol |
| Already running base protocol, flares persist | Add SS-31 |
SS-31 stabilizes mitochondrial function during stress—but if tissue lacks blood flow (needs BPC-157), cellular mobility (needs TB-500), or baseline energy (needs NAD+), there's less to stabilize. The foundation matters.
However: If you have clear evidence of mitochondrial dysfunction (confirmed by functional testing, or a pattern of post-exertional crashes that doesn't respond to other interventions), SS-31 can be used earlier in the protocol stack.
The Physiologic Problem
Most rehab ends when pain resolves, but durable recovery often fails at a quieter bottleneck: mitochondrial instability during stress.
When mitochondria leak electrons (during spikes in training stress, poor sleep, under-fueling, or aggressive rehab progression), reactive oxygen species (ROS) rises, inflammatory signaling reactivates, and you get the classic "two steps forward, one step back."
| Before SS-31 | After SS-31 |
|---|---|
| Energy production variable; drops under stress | More consistent output during loading blocks |
| Residual ROS → micro-inflammation after sessions | Lower electron leak, fewer ROS spikes |
| Collagen remodeling starts but doesn't "stick" | More predictable consolidation week-to-week |
| Fatigue and guarding return with load | Less relapse pressure from metabolic stress |
| Reactive, oscillating progress | Stable progression tolerance |
How SS-31 Works for Injury Recovery
SS-31 is a mitochondria-targeted peptide that localizes to the inner mitochondrial membrane and interacts with cardiolipin—the lipid that holds the electron transport chain together.
Cardiolipin: The Core Problem
Cardiolipin is a unique phospholipid found almost exclusively on the inner mitochondrial membrane. It anchors the respiratory complexes (I, III, IV) and cytochrome c, enabling efficient electron transfer. When cardiolipin is damaged—from aging, inflammation, ischemia-reperfusion, or chronic injury—several things go wrong:
- Electron leak increases → ROS production spikes
- Cytochrome c detaches → Can trigger apoptotic signaling
- ATP production drops → Less energy per oxygen molecule
- Inflammatory cascades activate → NF-κB, TNF-α upregulation
This is why tissue feels "tired" even when structure is intact. The machinery is inefficient.
What SS-31 Does for Injury Recovery
SS-31 (sequence: D-Arg-Dmt-Lys-Phe-NH₂) concentrates 1,000–5,000× in mitochondria within minutes of administration. It binds cardiolipin and:
| Mechanism | Effect | What You Notice |
|---|---|---|
| Cardiolipin stabilization | Tightens respiratory chain, reduces electron leak | More ATP per unit oxygen |
| Cytochrome c peroxidase inhibition | Prevents cardiolipin oxidation cascade | Less oxidative damage during stress |
| ROS reduction | Direct scavenging + source reduction | Soreness resolves faster post-session |
| SIRT1 upregulation | Enhanced mitochondrial biogenesis signaling | Better long-term adaptation |
| NF-κB/TNF-α suppression | Reduced inflammatory reactivation | Fewer "mystery flares" after heavy days |
| Glutathione preservation | Maintains antioxidant capacity | More resilience under repeated stress |
The practical claim is not "SS-31 heals tendons." The claim is: mitochondrial output becomes steadier under stress, which reduces relapse pressure during progressive loading. The tissue has the energy it needs to consolidate repair instead of repeatedly re-inflaming.
Injury Recovery Dosing Protocol
Continue your base protocol (BPC-157 + TB-500 + NAD+ + GHK-Cu + KPV). This module adds:
| Phase | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Load | 5–10 mg | Daily | 2–4 weeks | Prioritize consistency over dose escalation |
| Maintain | 5–10 mg | 2–3× weekly | 4–8+ weeks | Use minimum frequency that keeps rehab stable |
Route: IV or IM in clinical settings; SubQ may be used with appropriate guidance
Weekly Schedule (Example)
Base protocol continues as normal. Add:
Loading Phase (Weeks 1–4)
| Add-On | Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|---|
| SS-31 | 5 mg | 5 mg | 5 mg | 5 mg | 5 mg | 5 mg | 5 mg |
Maintenance Phase (Weeks 5+)
| Add-On | Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|---|
| SS-31 | 5 mg | — | 5 mg | — | 5 mg | — | — |
Injury Recovery Timeline
Weeks 1–2
- What's happening: Cardiolipin stabilization begins
- What you notice: Post-session recovery feels cleaner
- Challenge: Stay consistent; don't expect immediate changes
Weeks 2–4
- What's happening: ATP efficiency improves
- What you notice: Load tolerance rises; fewer flares
- Decision point: Can begin transitioning to maintenance frequency
Weeks 4–8
- What's happening: Consolidation under load
- What you notice: Progress becomes predictable
- Maintenance: Reduce to 2–3× weekly if stable
What "Working" Looks Like
- Post-session flare frequency drops
- Recovery becomes predictable (less "random" soreness/stiffness)
- You can increase rehab load without triggering multi-day setbacks
- Tissue feels stable rather than reactive
If you feel a transient "boost" but flare patterns don't change, mitochondrial instability may not be your limiter.
Injury Recovery Implementation Notes
- Timing: Morning or pre-training typically works well
- Route: IV or IM (clinical settings); SubQ may be used with appropriate guidance
- Mixing: Inject alone; do not mix with other peptides in same syringe
- Adjustment: If injection site irritation or fatigue occurs, reduce frequency first
Signs of Success
- No residual pain/swelling after heavy training weeks
- Strength and endurance equal or better than pre-injury
- Sleep quality consistently high
- Energy stable even with stacked work/life stress
Maintenance Options
When all criteria are met:
- Stop entirely: Many people discontinue after 8–12 week protocols
- Periodic blocks: Short SS-31 cycles (4–6 weeks) every 6–12 months for long-term resilience
- Simpler maintenance: NAD+ support plus lifestyle if that's sufficient
Conditioning Support: Optional Add-On
After SS-31 establishes mitochondrial stability, some people add MOTS-c and L-Carnitine for conditioning capacity:
| Compound | Role | When to Add |
|---|---|---|
| MOTS-c | AMPK activation, mitochondrial biogenesis | When tissue is stable but work capacity lags |
| L-Carnitine | Fatty acid transport, β-oxidation support | Same—capacity is the limiter, not stability |
This is optional and appropriate only after structural repair is complete and stable under load. If adding MOTS-c/L-Carnitine increases flare-ups, step back to SS-31 stability first.
Injury Recovery FAQ
What is SS-31 and how does it work for injury recovery?
SS-31 (Elamipretide) is a mitochondria-targeted peptide that binds to cardiolipin on the inner mitochondrial membrane. Cardiolipin holds the electron transport chain together—when it's damaged, electrons leak and create oxidative stress instead of ATP. SS-31 stabilizes cardiolipin, tightening the respiratory chain so more oxygen becomes energy and less becomes damaging ROS.
Who is SS-31 designed for in injury recovery?
SS-31 is an advanced protocol for people who have completed foundational repair (BPC-157/TB-500), metabolic support (NAD+/GHK-Cu/KPV), and hormonal timing (Tesamorelin if needed)—but still experience relapse under load. It's for the "almost healed, but keeps flaring" pattern where tissue is structurally sound but reactive to stress.
How is SS-31 different from NAD+?
NAD+ is a redox cofactor—it carries electrons in the metabolic pathways that generate ATP. SS-31 targets the mitochondrial membrane structure itself, stabilizing the electron transport chain so those electrons don't leak. They work through different mechanisms and can be used together: NAD+ provides the substrate, SS-31 ensures the machinery runs efficiently.
What does SS-31 feel like when it's working?
You'll notice post-session flare frequency drops, recovery becomes predictable instead of oscillating, you can increase training load without triggering multi-day setbacks, energy feels steadier under stress, and soreness resolves faster.
How long does an SS-31 cycle last?
Typical cycles are 8–12 weeks: 2–4 weeks of daily loading, then 4–8 weeks of maintenance (2–3× weekly). Some people repeat cycles every 6–12 months for long-term resilience. Others stop entirely after achieving stability.
What if I still flare after starting SS-31?
- Verify dosing and timing are consistent
- Check if the limiter is actually mitochondrial (vs. neural, hormonal, or programming)
- Consider extending the loading phase before reducing frequency
- Reassess training intensity—if load is too aggressive, no compound fixes that
- Consider ARA-290 if nerve symptoms are present
- Consider Tesamorelin if sleep/GH timing is disrupted
- Discuss with your clinician whether earlier protocol layers need adjustment
Can I combine SS-31 with Tesamorelin or ARA-290?
Yes. They address different bottlenecks:
- SS-31: Mitochondrial stability under load
- Tesamorelin: GH timing and sleep-timed repair
- ARA-290: Small-fiber nerve healing
These can be combined if you have multiple limiting factors. They work through independent pathways and don't interfere with each other.
Related Topics
- MOTS-c Guide — exercise mimetic for metabolic adaptation
- NAD+ Guide — essential cofactor for mitochondrial function
- Mitochondrial Stack — SS-31 + MOTS-c + NAD+ combined
- Tesamorelin Guide — GH-axis support for energy and recomposition
- GLP-1 Comparison — metabolic interventions (SS-31 supports during rapid fat loss)
References
- Thompson WR, Hornby B, Manuel R, et al. A phase 2/3 randomized clinical trial of elamipretide in Barth syndrome. Genet Med 2021. https://www.nature.com/articles/s41436-020-01006-8
- Thompson WR, Manuel R, Batzner A, et al. TAZPOWER: 168-Week Open-Label Extension. Genet Med 2024. https://pubmed.ncbi.nlm.nih.gov/38602181/
- Karaa A, Haas R, Goldstein A, et al. MMPOWER-3: Primary Mitochondrial Myopathy. Neurology 2023. https://pubmed.ncbi.nlm.nih.gov/37268435/
- Siegel MP, Kruse SE, Percival JM, et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide. PLoS ONE 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8282018/
- Sabbah HN, Gupta RC, Kohli S, et al. Elamipretide improves mitochondrial function in the failing human heart. JACC Basic Transl Sci 2019. https://www.jacc.org/doi/10.1016/j.jacbts.2018.12.005
- Szeto HH, Liu S. Cardiolipin-targeted peptides rejuvenate mitochondrial function, remodel mitochondria, and promote tissue regeneration. Int J Mol Sci 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11816484/
This content is for educational purposes only. Elamipretide (Forzinity) is FDA-approved for Barth syndrome. For all other uses, it remains investigational and is available through research suppliers, compounding pharmacies, or expanded-access programs. Work with a qualified healthcare provider before starting any peptide protocol.
Medical Disclaimer
The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.